Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares fell 4.5% during mid-day trading on Wednesday . The company traded as low as $11.15 and last traded at $11.1650. 16,654 shares were traded during trading, a decline of 92% from the average daily volume of 196,120 shares. The stock had previously closed at $11.69.

Wall Street Analyst Weigh In

TLX has been the subject of a number of recent analyst reports. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.40.

Telix Pharmaceuticals Price Performance

The company has a 50 day moving average of $11.05 and a 200-day moving average of $9.73. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01.

Institutional Trading of Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the 4th quarter worth $89,000. Bank of America Corp DE increased its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the last quarter. OLD Mission Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the 4th quarter valued at $111,000. Finally, XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.